HUP0100850A2 - Fokozott biológiai hasznosulású, molekulárisan diszpergált készítmény - Google Patents

Fokozott biológiai hasznosulású, molekulárisan diszpergált készítmény

Info

Publication number
HUP0100850A2
HUP0100850A2 HU0100850A HUP0100850A HUP0100850A2 HU P0100850 A2 HUP0100850 A2 HU P0100850A2 HU 0100850 A HU0100850 A HU 0100850A HU P0100850 A HUP0100850 A HU P0100850A HU P0100850 A2 HUP0100850 A2 HU P0100850A2
Authority
HU
Hungary
Prior art keywords
molecular dispersion
dispersion composition
polymer
enhanced bioavailability
hydroxypropyl
Prior art date
Application number
HU0100850A
Other languages
English (en)
Inventor
Ping I. Lee
Amin A. Nomeir
Surendra A. Sangekar
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0100850A2 publication Critical patent/HUP0100850A2/hu
Publication of HUP0100850A3 publication Critical patent/HUP0100850A3/hu
Publication of HU229052B1 publication Critical patent/HU229052B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát egy molekuláris diszperziót tartalmazó, fokozottbiológiai hasznosulású gyógyszerkészítmény képezi, amely molekulárisdiszperzió tartalmaz egy polimer mátrixban molekulárisan diszpergált(+) - enantiomer képletű vegyületet. A polimer mátrix egy vízbenoldódó polimert, így poli(vinil-pirrolidon)-t, (hidroxi-propil)-metil-cellulózt, (hidroxi-propil)-cellulózt vagy polietilénglikolttartalmaz. Az (I) képletű vegyület és a polimer aránya körülbelül1:0,5 és körülbelül 1:4 között van. A találmány tárgyát képezi továbbáa fenti molekuláris diszperzió mellett szétesést elősegítő anyagot,síkosító anyagot, felületaktív anyagot és valamilyen siklatót istartalmazó tabletta vagy kapszula is. Ó
HU0100850A 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability HU229052B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99716897A 1997-12-22 1997-12-22
PCT/US1998/026218 WO1999032118A1 (en) 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability

Publications (3)

Publication Number Publication Date
HUP0100850A2 true HUP0100850A2 (hu) 2001-10-28
HUP0100850A3 HUP0100850A3 (en) 2002-12-28
HU229052B1 HU229052B1 (en) 2013-07-29

Family

ID=25543717

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100850A HU229052B1 (en) 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability

Country Status (28)

Country Link
EP (1) EP1039908B1 (hu)
JP (2) JP2001526227A (hu)
KR (1) KR100597331B1 (hu)
CN (1) CN1116039C (hu)
AR (1) AR017436A1 (hu)
AT (1) ATE260105T1 (hu)
AU (1) AU761994C (hu)
BR (1) BR9813728A (hu)
CA (1) CA2315685C (hu)
CO (1) CO4970793A1 (hu)
CZ (1) CZ295956B6 (hu)
DE (1) DE69821984T2 (hu)
DK (1) DK1039908T3 (hu)
ES (1) ES2214757T3 (hu)
HK (1) HK1027040A1 (hu)
HU (1) HU229052B1 (hu)
ID (1) ID28304A (hu)
IL (1) IL136460A0 (hu)
MY (1) MY126580A (hu)
NO (1) NO327383B1 (hu)
NZ (1) NZ504834A (hu)
PE (1) PE20000012A1 (hu)
PL (1) PL192423B1 (hu)
PT (1) PT1039908E (hu)
SK (1) SK285662B6 (hu)
TW (1) TW527196B (hu)
WO (1) WO1999032118A1 (hu)
ZA (1) ZA9811592B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
AU2003217909C1 (en) * 2002-03-04 2009-06-11 Teva Pharmaceutical Industries Ltd. Controlled release dosage forms
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PT103661B (pt) 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
CA2124821C (en) * 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
JPH0848632A (ja) * 1994-08-08 1996-02-20 Kanebo Ltd エトポシドを含有する固形組成物および固形製剤
NZ326035A (en) * 1995-12-22 2000-01-28 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability

Also Published As

Publication number Publication date
KR20010033397A (ko) 2001-04-25
NO327383B1 (no) 2009-06-22
ES2214757T3 (es) 2004-09-16
NZ504834A (en) 2001-12-21
IL136460A0 (en) 2001-06-14
ATE260105T1 (de) 2004-03-15
JP2001526227A (ja) 2001-12-18
CZ20002304A3 (cs) 2001-04-11
CA2315685C (en) 2008-02-05
CO4970793A1 (es) 2000-11-07
SK8962000A3 (en) 2001-07-10
JP2010059212A (ja) 2010-03-18
DE69821984T2 (de) 2004-12-30
DE69821984D1 (de) 2004-04-01
TW527196B (en) 2003-04-11
KR100597331B1 (ko) 2006-07-10
AU761994B2 (en) 2003-06-12
WO1999032118A1 (en) 1999-07-01
DK1039908T3 (da) 2004-05-03
AU761994C (en) 2004-01-08
EP1039908A1 (en) 2000-10-04
NO20003235L (no) 2000-07-27
HUP0100850A3 (en) 2002-12-28
CN1282245A (zh) 2001-01-31
SK285662B6 (sk) 2007-05-03
CA2315685A1 (en) 1999-07-01
CZ295956B6 (cs) 2005-12-14
NO20003235D0 (no) 2000-06-21
CN1116039C (zh) 2003-07-30
PL192423B1 (pl) 2006-10-31
PT1039908E (pt) 2004-06-30
HK1027040A1 (en) 2001-01-05
EP1039908B1 (en) 2004-02-25
PE20000012A1 (es) 2000-01-18
AR017436A1 (es) 2001-09-05
PL341344A1 (en) 2001-04-09
AU1814399A (en) 1999-07-12
HU229052B1 (en) 2013-07-29
BR9813728A (pt) 2000-10-10
MY126580A (en) 2006-10-31
ID28304A (id) 2001-05-10
ZA9811592B (en) 1999-06-17

Similar Documents

Publication Publication Date Title
KR100439614B1 (ko) 가교결합된아밀로즈및하이드록시프로필메틸셀룰로즈계담체를함유하는서방성약제학적정제
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
HUP9702424A2 (hu) Olvadékextrudált szilárd hatóanyag-készítmények
RU94043772A (ru) Пропинил-диароматические соединения, фармацевтические и косметические составы на их основе
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
HUP9903384A2 (hu) Izomalttartalmú polimerhatóanyag-olvadék extrudálásával nyert szilárd gyógyszerformák
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
IL123010A (en) Pharmaceutical compositions of l-dopa ethyl ester
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
HUP9801700A2 (hu) Monomer inzulin analóg tartalmú készítmények
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97015A1 (fr) Nouveaux derives de 19-nor-pregnene.
HUP0100850A2 (hu) Fokozott biológiai hasznosulású, molekulárisan diszpergált készítmény
HUP0402492A2 (hu) 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények
HUP0400382A2 (hu) Késleltetett leadású készítmény és eljárás annak előállítására
BR9507489A (pt) Derivados tropano sua preparacão e uso
HUP0004405A2 (hu) Polietilénglikol mátrixszemcsék zsíros, olajos vagy ragacsos gyógyszerhatóanyagokhoz
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
HUP0001780A2 (hu) Stabilizált tibolont tartalmazó készítmények és eljárás előállításukra

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US

MM4A Lapse of definitive patent protection due to non-payment of fees